As KMT2A rearrangement and BCR-ABL1 are poor prognostic factors but potentially druggable lesions in pediatric BCP-ALL, we analyzed the prevalence of these two genetic lesions in BCP-L and investigated whether they could serve as prognostic markers or therapeutic targets in these patients. Here, KMT2A is linked to acute lymphoblastic leukemia.